Literature DB >> 28421817

Sequential Granulocyte-Macrophage Colony-Stimulating Factor Inhalation after Whole-Lung Lavage for Pulmonary Alveolar Proteinosis. A Report of Five Intractable Cases.

Shinya Ohkouchi1,2, Keiichi Akasaka3,4, Toshio Ichiwata5, Shu Hisata1, Hideya Iijima6, Toshinori Takada3, Hiroki Tsukada7, Hideaki Nakayama8, Jun-Ichi Machiya9, Toshiya Irokawa2, Hiromasa Ogawa2, Yoko Shibata10, Masakazu Ichinose1, Masahito Ebina11, Toshihiro Nukiwa12, Hajime Kurosawa2, Koh Nakata13, Ryushi Tazawa13.   

Abstract

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by the excessive accumulation of surfactant proteins within the alveolar spaces and by higher titers of autoantibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) in the serum and bronchoalveolar lavage fluid. The antibodies inhibit the maturation and phagocytosis of alveolar macrophages. Although the standard therapy for aPAP has been whole-lung lavage (WLL), this procedure is invasive and needs to be repeated for several years. GM-CSF inhalation therapy is a new procedure for treating aPAP and can induce remission with less invasiveness, although it is generally less effective in severe cases. We evaluated five cases with remarkable improvement by using sequential GM-CSF inhalation therapy after WLL; however, the treatment failed when this therapy preceded WLL. Therefore, sequential GM-CSF inhalation after WLL may reinforce the efficiency of WLL in patients with severe aPAP.

Entities:  

Keywords:  autoimmune pulmonary alveolar proteinosis; granulocyte-macrophage colony-stimulating factor; inhalation; whole-lung lavage

Mesh:

Substances:

Year:  2017        PMID: 28421817     DOI: 10.1513/AnnalsATS.201611-892BC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  6 in total

1.  Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up.

Authors:  Xinlun Tian; Yanli Yang; Lulu Chen; Xin Sui; Wenshuai Xu; Xue Li; Xiaobei Guo; Lingshan Liu; Yusen Situ; Jun Wang; Yang Zhao; Shuzhen Meng; Wei Song; Yonglong Xiao; Kai-Feng Xu
Journal:  Orphanet J Rare Dis       Date:  2020-07-02       Impact factor: 4.123

2.  Better approach for autoimmune pulmonary alveolar proteinosis treatment: inhaled or subcutaneous granulocyte-macrophage colony-stimulating factor: a meta-analyses.

Authors:  Gaohong Sheng; Peng Chen; Yanqiu Wei; Jiaojiao Chu; Xiaolei Cao; Hui-Lan Zhang
Journal:  Respir Res       Date:  2018-08-31

3.  Opportunistic Infection Associated With Elevated GM-CSF Autoantibodies: A Case Series and Review of the Literature.

Authors:  Elinor Lee; Christopher Miller; Ali Ataya; Tisha Wang
Journal:  Open Forum Infect Dis       Date:  2022-04-09       Impact factor: 4.423

4.  Alveolar proteinosis due to toxic inhalation at workplace.

Authors:  Gabriela F Santos; João Portela; Despoina Argyropoulou; Rita Varudo; Inês Pimenta; Ana Oliveira; Sara Lança; Antero Fernandes
Journal:  Respir Med Case Rep       Date:  2020-08-26

5.  Autoimmune pulmonary alveolar proteinosis successfully treated with lung lavage in an adolescent patient: a case report.

Authors:  Abdalla Mohmed Alasiri; Reem Abdullah Alasbali; Meaad Ali Alaqil; Aishah Marei Alahmari; Nouf Dagash Alshamrani; Rabab Nasir Badri
Journal:  J Med Case Rep       Date:  2021-07-09

Review 6.  GM-CSF: Orchestrating the Pulmonary Response to Infection.

Authors:  Thomas S McCormick; Rana B Hejal; Luis O Leal; Mahmoud A Ghannoum
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.